Environmental distribution of certain modified live-virus vaccines with a high safety profile presents a low-risk, high-reward to control zoonotic diseases.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 05 2019
01 05 2019
Historique:
received:
28
01
2019
accepted:
05
04
2019
entrez:
3
5
2019
pubmed:
3
5
2019
medline:
24
10
2020
Statut:
epublish
Résumé
Oral vaccines aid immunization of hard to reach animal populations but often contain live-attenuated viruses that pose risks of reversion to virulence or residual pathogenicity. Human risk assessment is crucial prior to vaccine field distribution but there is currently no standardized approach. We mapped exposure pathways by which distribution of oral vaccines may result in inoculation into people and applied a Markov chain to estimate the number of severe adverse events. We simulated three oral rabies vaccination (ORV) campaigns: (1) first generation ORV (SAD-B19) in foxes, (2) SAD-B19 in dogs, and (3) third generation ORV (SPBN GASGAS) in dogs. The risk of SAD-B19-associated human deaths was predicted to be low (0.18 per 10 million baits, 95% CI: 0.08, 0.36) when distributed to foxes, but, consistent with international concern, 19 times greater (3.35 per 10 million baits, 95% CI: 2.83, 3.98) when distributed to dogs. We simulated no deaths from SPBN GAS-GAS. Human deaths during dog campaigns were particularly sensitive to dog bite rate, and during wildlife campaigns to animal consumption rate and human contact rate with unconsumed baits. This model highlights the safety of third generation rabies vaccines and serves as a platform for standardized approaches to inform risk assessments.
Identifiants
pubmed: 31043646
doi: 10.1038/s41598-019-42714-9
pii: 10.1038/s41598-019-42714-9
pmc: PMC6494895
doi:
Substances chimiques
Rabies Vaccines
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
6783Références
Vaccine. 1992;10(8):524-8
pubmed: 1621416
Front Vet Sci. 2017 Feb 10;4:9
pubmed: 28239608
MMWR Morb Mortal Wkly Rep. 2018 Mar 09;67(9):286
pubmed: 29518066
J Clin Immunol. 2014 Nov;34(8):954-61
pubmed: 25257253
J Wildl Dis. 2014 Apr;50(2):397-401
pubmed: 24484500
Berl Munch Tierarztl Wochenschr. 2004 Sep-Oct;117(9-10):360-6
pubmed: 15495926
MMWR Morb Mortal Wkly Rep. 2013 Apr 12;62(14):267-9
pubmed: 23575240
Vaccine. 1996 Nov;14(16):1506-10
pubmed: 9014291
J Wildl Dis. 2002 Apr;38(2):428-31
pubmed: 12038143
Vaccine. 2016 Sep 22;34(41):5021-5025
pubmed: 27576075
Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120142
pubmed: 23798690
PLoS One. 2017 Oct 12;12(10):e0185594
pubmed: 29023555
J Virol. 2002 Apr;76(7):3374-81
pubmed: 11884563
Nature. 2008 Feb 21;451(7181):990-3
pubmed: 18288193
Proc Natl Acad Sci U S A. 1983 Jan;80(1):70-4
pubmed: 6185960
J Virol. 2005 Nov;79(22):14141-8
pubmed: 16254349
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):498-505
pubmed: 23572010
Dtsch Tierarztl Wochenschr. 2002 Oct;109(10):428-32
pubmed: 12448972
Expert Rev Vaccines. 2011 Aug;10(8):1221-40
pubmed: 21854314
J Gen Virol. 1980 May;48(1):105-9
pubmed: 6155432
Zoonoses Public Health. 2018 Sep;65(6):711-727
pubmed: 29931738
BMC Vet Res. 2018 Mar 13;14(1):90
pubmed: 29534727
J Am Vet Med Assoc. 1998 Nov 15;213(10):1413-7
pubmed: 9828931
J Travel Med. 2013 May-Jun;20(3):148-58
pubmed: 23577860
Proc Natl Acad Sci U S A. 1984 Nov;81(22):7194-8
pubmed: 6095272
Infect Dis Clin North Am. 2014 Sep;28(3):323-37
pubmed: 25151559
J Am Vet Med Assoc. 2012 Jan 15;240(2):163-8
pubmed: 22217024
Hybrid Hybridomics. 2002 Apr;21(2):123-7
pubmed: 12031102
Vaccine. 2008 Jan 17;26(3):419-26
pubmed: 18082293
Arch Virol. 2009;154(7):1081-91
pubmed: 19521660
Vet J. 2007 Nov;174(3):472-80
pubmed: 17113798
N Engl J Med. 2001 Aug 23;345(8):582-6
pubmed: 11529212
Lancet Glob Health. 2017 Oct;5(10):e1017-e1025
pubmed: 28911750
Front Vet Sci. 2018 May 18;5:91
pubmed: 29868616
Epidemiol Infect. 1999 Aug;123(1):165-75
pubmed: 10487653
Vaccine. 1996 Sep;14(13):1257-64
pubmed: 8961515
PLoS Negl Trop Dis. 2015 Aug 17;9(8):e0003953
pubmed: 26280895
MMWR Morb Mortal Wkly Rep. 2009 Nov 6;58(43):1204-7
pubmed: 19893480
J Wildl Dis. 2008 Jan;44(1):71-85
pubmed: 18263823
Proc Biol Sci. 2009 Aug 22;276(1669):2987-95
pubmed: 19493904
J Virol. 2007 Jul;81(13):7041-7
pubmed: 17459937
J Wildl Dis. 2004 Apr;40(2):222-9
pubmed: 15362821
Virology. 1990 Apr;175(2):485-99
pubmed: 2139267
Vaccine. 2019 Aug 2;37(33):4750-4757
pubmed: 29042202
PLoS One. 2013 Jul 23;8(7):e70126
pubmed: 23894603
Vaccine. 2018 Feb 1;36(6):811-817
pubmed: 29325820
Vaccine. 2019 Aug 2;37(33):4758-4765
pubmed: 29439868